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Abstract
Metastatic tumor cells in body fluids are important targets for treatment, and critical surrogate markers for evaluating
cancer prognosis and therapeutic response. Here we report, for the first time, that live metastatic tumor cells in blood
samples from mice bearing human tumor xenografts and in blood and cerebrospinal fluid samples from patients with
cancer were successfully detected using a tumor cell-specific recombinant vaccinia virus (VACV). In contrast to the FDA-
approved CellSearch system, VACV detects circulating tumor cells (CTCs) in a cancer biomarker-independent manner, thus,
free of any bias related to the use of antibodies, and can be potentially a universal system for detection of live CTCs of any
tumor type, not limited to CTCs of epithelial origin. Furthermore, we demonstrate for the first time that VACV was effective
in preventing and reducing circulating tumor cells in mice bearing human tumor xenografts. Importantly, a single intra-
peritoneal delivery of VACV resulted in a dramatic decline in the number of tumor cells in the ascitic fluid from a patient
with gastric cancer. Taken together, these results suggest VACV to be a useful tool for quantitative detection of live tumor
cells in liquid biopsies as well as a potentially effective treatment for reducing or eliminating live tumor cells in body fluids
of patients with metastatic disease.
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Introduction
Most cancer deaths result from the metastatic spread of cancer
in which tumor cells escape from the primary tumor, relocate to
distant sites and initiate new tumors [1]. Metastatic tumor cells
found in body fluids such as blood, lymphatic, cerebrospinal and
ascitic fluids have become important biomarkers in evaluating
cancer prognosis and for monitoring therapeutic response.
Importantly, prevention and elimination of such metastatic tumor
cells may result in a significant reduction in morbidity and
mortality.
Metastatic tumor cells in the peripheral blood, referred to as
circulating tumor cells (CTCs), have been shown to be a
prognostic biomarker for several types of solid tumors, including
non-small cell lung cancer, breast cancer, colorectal cancer and
prostate cancer [2–3]. Different methods have been investigated
for the detection of CTCs [3]. Only the immunomagnetic
technique-based platform CellSearchH (Veridex, Warren, NJ,
USA) has been approved by the US Food and Drug Administra-
tion (FDA) for the detection of CTCs in breast, colon and prostate
cancer patients [2]. However, detection by antibody-based
techniques can present significant uncertainty due to the
heterogeneity of antigen expression of CTCs. Hence, there is an
urgent need for the development of a more comprehensive,
sensitive, and cancer cell-specific method for CTC detection in
order to improve the utility and potential benefit of CTC analysis
in the clinic [3].
The spread of metastatic tumor cells to the cerebrospinal fluid
(CSF) and leptomeninges results in leptomeningeal metastases
(LM). The incidence of LM in cancer patients ranges between 5
and 15% and likely is on the rise as the survival of cancer patients
increases. LM might also be underdiagnosed since some metas-
tases may remain asymptomatic [4]. The prognosis for patients
with LM is extremely poor with the median survival measured in
months [5]. Treatment of LM is mainly palliative. Early diagnosis
and effective treatment are critical to prevent important neuro-
logical deficits, improve quality of life and prolong survival.
Methods for the diagnosis of LM include clinical examination,
neuroimaging, and CSF analysis. Currently, the leading diagnostic
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laboratory test for LM is cytological examination of the CSF, a
method with limited sensitivity and specificity.
Peritoneal carcinomatosis (PC) is the locoregional progression of
cancers, being mostly of gastrointestinal and gynecological origins.
At the time of diagnosis, about 10 to 15% of patients with
gastrointestinal and gynecological cancers have already developed
PC, a terminal condition and a consequence of the underlying
systemic nature of the disease [6]. Treatment with cytoreductive
surgery, followed by hyperthermic intraperitoneal chemotherapy
has demonstrated a significant survival benefit [7]. This treatment,
however, is expensive and is associated with a very high
postoperative morbidity rate, ranging from 25 to 56% [6].
Recombinant vaccinia viruses (VACVs) carrying imaging genes
have emerged as potential combined therapeutic and diagnostic
agents (theranostics) due to their oncolytic potential and tumor
specificity [8]. Using this VACV technology in combination with a
cytospin slide-based system, we developed a simple, sensitive,
specific, and widely applicable assay to successfully detect and
enumerate live tumor cells in both preclinical and clinical liquid
biopsies in an epithelial biomarker-independent manner. Unlike
the FDA approved CellSearchH system, which relies on antibody-
based detection of cell surface antigens of CTCs, VACV detection
requires infection and expression of the virus-encoded marker
protein by the target cell, thus only live CTCs are detected.
Furthermore, we demonstrated that VACV infected and reduced
live metastatic tumor cells both in the blood of mice bearing
metastatic prostate cancer xenografts and in the ascitic fluid of a
cancer patient with peritoneal carcinomatosis.
Materials and Methods
Cell Lines
The human prostate cancer cell line PC-3 and the human lung
carcinoma cell line A549 were purchased from the American Type
Culture Collection. The human prostate cancer cell line PC-3-
RFP was generated as described previously [9]. HT-29 and A549
cells were cultured in RPMI 1640 (Mediatech, Manassas, VA,
USA) supplemented with 10% FBS (Mediatech, Manassas, VA,
USA). PC-3 cells were cultured in DMEM (Mediatech, Manassas,
VA, USA) supplemented with 10% FBS. PC-3RFP cells were
cultured in DMEM-supplemented with 10% FBS and 10 mg/ml of
blasticidin. Cells were maintained at 37uC in a humidified
atmosphere containing 5% CO2.
Viruses
The cDNA encoding for TurboFP635 was PCR-amplified using
the plasmid FUKW (kindly provided by Dr. Marco J. Herold,
University of Wurzburg) as a template with primers FUKW-5 (59-
GTCGAC (Sal I) CACCATGGTGGGTGAGGATAGCGTGC-
39) and FUKW-3 (59-TTAATTAA (Pac I) TCAGCTGTGCCC-
CAGTTTGC-39). The PCR product was gel-purified, and cloned
into the pCR-Blunt II-TOPO vector using Zero Blunt TOPO
PCR Cloning Kit (life Technologies, Carlsbad, CA, USA). The
resulting construct pCRII-FUKW was sequence confirmed. The
TurboFP635 cDNA was then released from pCRII-FUKW with
Sal I and Pac I, and subcloned into the VACV A56R (hemagglu-
tinin, HA) shuttle vector HA-SL-hNET1 with the same cuts to
replace the hNET cDNA. The resulting construct HA-SL-
FUKW2 was sequence confirmed, and used to generate the
recombinant virus GLV-1h254 using GLV-1h71 as the parental
virus. GLV-1h68 and GLV-1h71 were described previously [10–
11]. A schematic overview of the VACV strains used in this study
is shown in Figure S1.
Mouse Tumor Xenograft Models
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol of this study was approved by the Institutional Animal
Care and Use Committee of Explora Biolabs (San Diego Science
Center, San Diego, CA, USA; protocol number: EB11-025). Five-
to six-week old nude mice (NCI:Hsd:Athymic Nude-Foxn1nu;
Harlan, Indianapolis, IN, USA) were implanted subcutaneously
with 56106 PC-3, PC-3RFP or A549 cells (in 100 mL PBS) on the
right hind leg.
Blood Sample Collection
Blood samples from healthy human donors were obtained from
the San Diego Blood Bank (San Diego, CA, USA). Blood samples
from patients with metastatic cancer were collected from the
Pacific Oncology and Hematology Clinic (Encinitas, CA, USA), or
Moores Cancer Center, the University of California, San Diego
(La Jolla, CA, USA). All blood donors gave their written informed
consent for study inclusion and were enrolled using the protocols
approved by the institutional review boards of the Pacific
Oncology and Hematology Clinic, and the University of
California, San Diego, respectively. The blood was collected into
EDTA tubes (BD Bioscience, San Jose, CA, USA). For the VACV-
cytospin assay and CellSearchH system comparison study, one
7.5 mL whole blood sample from each patient was collected into a
CellSave tube (Veridex, Raritan, NJ, USA) and shipped from the
Pacific Oncology and Hematology Clinic to the Genoptix
Laboratory (Carlsbad, CA, USA). Another 7.5 mL blood sample
of the same draw was collected into EDTA tubes and shipped to
Genelux Corporation (San Diego, CA, USA). To collect mouse
blood samples, mice were anesthetized with 1% to 1.5% isoflurane
and the blood was collected from the left ventricle of the heart into
EDTA tubes using a 26-G needle (BD Bioscience, San Jose, CA,
USA).
Cell Spiking
PC-3 cells were labeled with the green fluorescence dye PKH67
using PKH67 Green Fluorescent Cell Linker Kit for General Cell
Membrane Labeling (Sigma-Aldrich, St. Louis, MO, USA).
30,60 single cells were spiked into 100 mL healthy mouse blood
samples or 1 mL healthy human blood samples in triplicate. Blood
samples from six healthy human donors and six healthy mice were
tested.
Red Blood Cell Lysis
Mononuclear cells and circulating tumor cells were enriched
from whole blood samples by removing red blood cells with 16
RBC lysis buffer (eBioscience, San Diego, CA, USA) according to
the manufacturer’s instruction.
VACV Infection
The GLV-1h254 virus stock was diluted in DMEM supple-
mented with 2% FBS to yield a concentration of 26107 plaque-
forming units (pfu)/mL. Nucleated cells from 1 mL of the whole
blood following red blood cell lysis were resuspended in 0.5 mL of
the diluted virus and incubated at 37uC for 24 h.
Immunofluorescence Staining and Cell Deposition
Immunofluorescence staining procedures were carried out
according to the manufacturer’s instructions. After staining, cells
were washed once with 16DPBS and resuspended in 1 mL of 16
DPBS. Hettich cytospin chambers (Hettich, Germany) were
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assembled and the stained cell suspension was directly added into
cytospin reservoirs using a funnel card that creates cytospins with a
diameter of 8.7 mm. The cells were deposited onto clean glass grid
slides (VWR, West Chester, PA, USA) by centrifugation for 5
minutes at 1,500 rpm using a Hettich Universal 16 centrifuge
(Hettich, Germany). Slides were dried for 10 minutes at room
temperature. The 49, 6-diamidino-2-phenylindole (DAPI) HardSet
mounting medium (Vector Laboratories, Burlingame, CA, USA)
was used for cell nuclei staining.
Visualization and Enumeration of CTCs
An Olympus IX71 inverted epifluorescence microscope with
PictureFrameH software was used to image cells on grid slides. The
grids of each slide were checked for CTCs under the microscope
one grid at a time. Infected CTCs showed very strong
TurboFP635 expression together with staining positive for
epithelial cell adhesion molecule (EpCAM), pan-cytokeratin
(CK) and DAPI, but negative for CD45 (thus not leukocytes),
and met the morphologic characteristics consistent with malignant
cells, including large cellular size, high nuclear to cytoplasmic
ratio, and visible nucleoli, were scored as CTCs.
Detection of CTCs by the CellSearchH System
Samples were analyzed as previously described [12–13].
Collection and Processing of CSF Samples
CSF samples from human patient donors were collected at the
Moores Cancer Center, University of California, San Diego (La
Jolla, CA, USA). All enrolled patients gave their written informed
consent for study inclusion and were enrolled using the protocol
approved by the institutional review board of the University of
California, San Diego. Three to five mL CSF from each patient
was collected. CSF samples were concentrated by centrifugation at
3006 g for 5 minutes at room temperature. VACV infection and
immunofluorescene staining were performed as described for
CTCs above. Cells on the slide were imaged and enumerated
under an epifluorescence microscope.
Prevention and Therapy of CTCs
Groups of 8 mice bearing PC-3RFP tumor xenografts were
treated with a single dose of 56106 pfu of GLV-1h68 (in 100 mL
of PBS) either at 4 weeks (early treatment) or 7 weeks (late
treatment) after tumor cell implantation. Mice treated with PBS at
4 weeks after implantation were used as controls. Mice were
monitored weekly for CTCs using Clearbridge BioMedics CTC0
Capture System Prototype [14]. 100 mL of blood were drawn from
mice through heart puncture and 80 mL were run through the
biochip. At death or at the end of the experiment, all mice were
dissected and examined for enlarged and/or fluorescing lumbar
renal lymph nodes. The images were acquired using a Leica MZ
16 FA stereo-fluorescence microscope equipped with a FireWire
DFC/IC monochrome CCD camera (Leica, Wetzlar, Germany).
Digital images were processed with Photoshop 7.0 (Adobe
Systems, Mountain View, USA).
Treatment of a Patient with Peritoneal Carcinomatosis
with GL-ONC1
Ascites from a patient with PC from gastric cancer, intraper-
itoneally treated with GL-ONC1 (clinical version of GLV-1h68),
were analyzed. First, the concentration of cells in the ascitic fluid
was determined. Then, the cells were collected by centrifugation,
followed by fixation of the cell pellet in formalin (4%, Fischer,
Germany) to a final concentration of 16106 cells/mL. After a
repeated centrifugation of this cell suspension, the supernatant was
discarded and the cell pellet was resuspended in a few drops of the
remaining supernatant. This suspension was collected and mixed
with hot agar (1% agarose), cooled, placed into a histology cassette
and fixed again in formalin (4%). The cassette was then embedded
in paraffin. From the resulting cell blocks, sections of 4 mm
thickness were cut, deparaffinised and rehydrated by passages
through xylene and graded alcohol and finally stained with
haematoxylin and eosin for morphologic evaluation. IHC staining
was performed using an automated immunohistochemistry stain-
ing system (VENTANA Benchmark; Ventana Medical Systems,
Tucson, AZ, USA), using reagents from VENTANA according to
the manufacturer’s protocol. Shortly, the slides were incubated
with primary antibodies VACV-A27L (Genelux, CA, USA); Ber-
EP4 (Dako, Germany) and visualized using iView DAB detection
kit (Ventana) with horseradish peroxidase and DAB as chromo-
gen. After DAB staining, slides were counterstained with
haematoxylin, washed, dehydrated in a graded alcohol series
and mounted with Cytosil (FISCHER Scientific, Germany). This
study was approved by the Paul-Ehrlich-Institut, Germany. The
trial was registered on http://www.clinicaltrials.gov (number
NCT01443260). Written, informed consent was obtained from
the patient.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism,
version 5.03 (GraphPad Software Inc., San Diego, CA). Statistical
analysis of survival was assessed using the log-rank test. Values of P
less than 0.05 were considered significant.
Results
Optimization and Evaluation of VACV-cytospin CTC
Detection Assay
In pilot experiments, the optimal viral dose for infection of
tumor cells in blood samples using TurboFP635-expressing
VACV, GLV-1h254, was determined to be 107 pfu per mL of
whole blood (Figure S2A). Using this dose, the capture efficiency,
detection efficiency, and specificity as well as infection efficiency of
the VACV-cytospin based CTC assay were evaluated. Thirty to
60 PC-3 human prostate cancer cells labeled with PKH67 (a green
fluorescent dye) were spiked into 1 mL of whole blood from
healthy human donors or 100 mL whole blood from healthy mice.
The spiked whole blood samples were subjected to red blood cell
lysis and VACV infection, followed by cytospin deposition. Each
experiment was performed in triplicate and six individual human
and mouse blood samples were used. The assay yielded similar
results with both the human and mouse blood samples (Table S1).
More than 70% of spiked tumor cells were captured on cytospin
slides (70% capture efficiency), and more than 92% of these cells
were infected by the virus (92% infection efficiency, for an overall
detection efficiency of 65%). 100% of the infected cells identified
on the slides were spiked tumor cells (100% detection specificity).
In the spiking experiments, PC-3 cells were labeled with the
PKH67 fluorescence dye and were washed before being spiked
into blood samples. Spiked blood samples were then subject to
RBC lysis and centrifugation before infection. All of these
manipulations might adversely affect the viability of cells. Thus,
not all spiked cells may have been alive at the time of infection,
which would explain why we only achieved 92% infection
efficiency, but not 100%.
To further demonstrate that GLV-1h254 specifically infected
only spiked tumor cells, but not healthy blood cells, both human
and mouse whole blood samples with or without spiked PC-3 cells
Detection and Therapy of Metastatic Tumor Cells
PLOS ONE | www.plosone.org 3 2013 | Volume 8 | Issue 9 | e71105September
were infected with GLV-1h254 and then stained with anti-human
or anti-mouse CD45 monoclonal antibodies to identify leukocytes.
All cells showing high-level expression of TurboFP635 (thus
infected with GLV-1h254) were CD45-negative, whereas all cells
staining positive for CD45 showed no TurboFP635 expression
(Figure S2B).
Detection and Identification of Live Human CTCs in
Blood Samples from Mice Bearing Human Tumor
Xenografts
The mouse xenograft model of human prostate cancer was
generated by implanting 56106 PC-3 tumor cells into the right
hind leg of nude mice. 100 mL of whole blood samples were taken
from these mice by cardiac puncture for CTC analysis using the
VACV-cytospin assay. Infection of blood samples with GLV-
1h254 ex vivo revealed microscopically that infected cells were
much larger than surrounding CD45+ immune cells, displayed
bright TurboFP635 fluorescent signal, contained nuclei, and were
CD452 (Figure 1A). These infected cells were also CK+ (Figure 1B)
or EpCAM+ (Figure 1C), indicating that the infected cells were of
epithelial origin, as expected for PC-3-derived CTCs. In another
experiment, CTCs were also detected and identified as Tur-
boFP635+/CD452/DAPI+ cells in mice bearing late-stage human
A549 non-small cell lung cancer xenografts (Figure 1D).
Detection and Identification of Live CTCs in Blood
Samples from Patients with Breast Cancer
Whole blood samples from seven patients with breast cancer
were analyzed using the VACV-cytospin assay (Table S2). The
volume of each sample varied from 5 to 15 mL. Live CTCs were
detected in three patients. No CTCs were found in the remaining
four patients (4–7 mL). To confirm the absence of CTCs in these
patients, the same blood samples were analyzed using immuno-
staining for CK and EpCAM. Again, no CTCs were detected.
Patient BC1 had stage III breast cancer with histological
diagnosis of estrogen receptor (ER)- negative, progesterone
receptor (PR)-negative and human epidermal growth factor
receptor 2 (HER2/neu)–negative, suggesting an aggressive disease,
and had been undergoing chemotherapy and irradiation treat-
ments before the blood sample was drawn. The VACV-cytospin
assay detected a total of 66 live CTCs in a 5.5 mL whole blood
sample. The CTCs identified by GLV-1h254 (TurboFP635+/
CD452/DAPI+) were also CK+ or EpCAM+ (Figure 1E). Another
patient, BC5, had stage I breast cancer with histological diagnosis
of ER-, PR+ and HER2/neu+. Fifteen live CTCs were detected in
a 5 mL blood sample from this patient. These live CTCs showed
not only EpCAM expression, but also PR and HER2/neu
expression (Figure 1F), consistent with the histological diagnosis.
Similar to patient BC1, patient BC7 also had stage III breast
cancer with histological diagnosis of ER-, PR- and HER2/neu-.
The patient had been undergoing chemotherapy, irradiation and
trastuzumab treatments before the blood sample was drawn. Only
3 live CTCs were found in a 3 mL blood sample. The CTCs were
identified as TurboFP635+/CK+/DAPI+ cells (Figure 1G).
Detection and Identification of Live CTCs in Blood
Samples from Patients with Other Types of Cancer
We analyzed blood samples from patients with metastatic
colorectal cancer, lung cancer and melanoma using the VACV-
cytospin assay (Table S3). Patient CC1 with metastatic colorectal
cancer had been undergoing chemotherapy and bevacizumab
treatments before the whole blood sample was drawn. Forty-one
live CTCs were detected in a 5 mL blood sample from this patient.
These infected live CTCs were confirmed as TurboFP635+/
EpCAM+ or CK+/CD452/DAPI+ cells (Figure 1H). The lung
cancer patient LC1 with brain metastases had not been
undergoing any treatment. Fourteen live CTCs were identified
in a 5 mL blood sample from this patient. These live CTCs also
displayed EpCAM expression (Figure 1I). Twenty-four live CTCs
were detected by GLV-1h254 in a 5 mL whole blood sample from
the patient MM1 with malignant metastatic cutaneous melanoma
and these CTCs were confirmed to express melanoma markers
microphthalmia-associated transcription factor or Melan-A
(Figure 1J).
Side-by-side Comparison of VACV-cytospin Assay and
CellSearchH System
Blood samples from 10 patients with metastatic breast cancer
and colon cancer were evaluated for CTCs using the two CTC
assays (Table S4). From each patient, one 7.5 mL blood sample
was collected in a CellSave tube and shipped to Genoptix
Laboratory (Carlsbad, CA) for CTC detection using the
CellSearchH system. Another 7.5 mL blood sample from the
same blood draw was collected in EDTA tubes and analyzed for
CTCs using the VACV-cytospin assay. The live CTCs identified
by VACV were confirmed with immunostaining as Tur-
boFP635+/CK+/CD452/DAPI+ cells. Both assays detected CTCs
in patients 1–4. In addition, the VACV-cytospin assay detected 2
CTCs in patient 7, but no CTCs were detected in this patient by
the CellSearchH system. Neither assay detected any CTCs in the
remaining 5 patients (Table 1). The VACV-cytospin assay
detected slightly more CTCs in patients 1 and 2, but a few less
CTCs in patient 3 than the CellSearchH system. Interestingly, the
CellSearchH system detected 103 CTCs in patient 4 while only 5
CTCs were identified using the VACV-cytospin assay, suggesting
most of the CTCs in patient 4 might not be alive since the
CellSearchH assay detects both live and dead CTCs whereas the
VACV-cytospin assay only detects live CTCs. In summary, 4 out
of 10 patients were positive for CTCs as determined by the
CellSearch system. All these patients (100%) were also reported to
be positive by the VACV-cytospin assay. Five of 6 patients (83%)
determined to not have CTCs by the CellSearch system were
confirmed to be negative for CTCs by the VACV-cytospin assay.
Thus, the sensitivity of the VACV-cytospin assay to the CellSearch
system was 100% with specificity of 83%, positive predictive value
of 100%, and negative predictive value of 83%.
Characterization of CTCs Identified in Blood Samples
from Mice with Human Tumor Xenografts and Patients
with Cancer
Recent studies have indicated that CTCs may be linked to both
cancer stem cells (CSCs) and the epithelial-mesenchymal transition
(EMT) process [15–16]. To elucidate the relationship of CTCs
with CSCs and EMT, we analyzed CTCs for the expression of
CSC and EMT markers. The CTCs identified with GLV-1h254
in mice bearing human PC-3 prostate cancer xenografts displayed
high levels of the expression of the CSC markers CD44 and
aldehyde dehydrogenase 1 (ALDH1) as well as the EMT markers
vimentin and N-cadherin (Figure 2A). Furthermore, the CTCs
identified in the breast cancer patients BC1 and BC5 showed high-
level expression of CD44 (Figure 2B) and ALDH1 (Figure 2C),
respectively. The features of CSCs as well as phenotypic change
characteristics of the EMT possessed by CTCs might allow them
to disseminate effectively during the progress of cancer metastases,
resulting in the formation of secondary tumors by extravasation
and colonization in distant organs.
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Figure 1. Detection and identification of live human CTCs in blood samples. (A) VACV GLV-1h254 detected live CTCs in mice bearing
human PC-3 prostate cancer xenografts. Infected CTCs were CK+ (B) or EpCAM+ (C). Live CTCs were also detected by GLV-1h254 in mice bearing
human A549 non-small lung cancer xenografts (D). (E) The live CTCs in the patient BC1 were identified as TurboFP635+/EpCAM+ or CK+/CD452/DAPI+
cells. (F) The live CTCs detected in the patient BC5 were confirmed to express EpCAM, PR, or HER2/neu markers. (G) The live CTCs in the patient BC7
were confirmed as TurboFP635+/CK+/DAPI+ cells. (H) The live CTCs in the patient CC1 with metastatic colorectal cancer were identified as
TurboFP635+/EpCAM+ or CK+/CD452/DAPI+ cells. (I) The live CTCs in the metastatic lung cancer patient LC1 were confirmed as TurboFP635+/EpCAM+/
DAPI+ cells. (J) The VACV detected live CTCs in the metastatic melanoma patient MM1 were shown to express melanoma tumor markers Melan-A or
microphthalmia-associated transcription factor.
doi:10.1371/journal.pone.0071105.g001
Table 1. Side-by-side comparison of VACV-Cytospin assay and CellSearchH system.
Patient ID 01 02 03 04 05 06 07 08 09 10
CTC # (CellSearchH) 7 27 5 103 0 0 0 0 0 0
Live CTC # (VACV) 10 35 2 5 0 0 2 0 0 0
Values indicate the number of CTCs per 7.5 mL of blood.
doi:10.1371/journal.pone.0071105.t001
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Detection and Identification of Live Cancer Cells in CSF
Samples from Patients with Cancer
CSF samples from seven patients with glioblastoma multiforme,
metastatic colorectal carcinoma, metastatic breast cancer and
metastatic esophageal cancer were analyzed using the VACV-
cytospin assay (Table S5). The volume of each sample ranged from
3 to 5 mL. A total of 23 TurboFP635+ cells with large nuclei were
found in the 3 mL CSF sample from the patient CSF7 with
metastatic breast cancer (Figure 3). Among these, 16 cells showed
high-level expression of CK (Figure 3A) and the rest of the infected
cells showed very low level or no expression of CK (Figure 3B). No
infected cells were found in the CSF samples from the other six
patients. To confirm the absence of cancer cells in these six CSF
samples, infected samples were further analyzed using immuno-
staining for CK. No CK+ cells were detected in these six patients
that were negative for TurboFP635.
Prevention and Therapy of CTCs in Mice Bearing Human
Prostate Cancer Xenografts
Nude mice were implanted with the modified human prostate
cancer cell line PC-3RFP, expressing red fluorescent protein (RFP)
on the right hind leg to facilitate CTC detection using the
ClearBridge biochip [14]. Mice were monitored for RFP-
expressing CTCs weekly after tumor cell implantation. CTCs
captured on the biochip were visualized and counted under a
fluorescent microscope. Mice were treated with a single intrave-
nous dose of 56106 pfu of GLV-1h68 (expressing GFP) either at 4
weeks (early treatment, n = 8) or at 7 weeks (late treatment, n = 8)
after tumor cell implantation. Mice treated with PBS at 4 weeks
after tumor cell implantation were used as controls (n = 7).
No CTCs were detected in any of the mice through 4 weeks
after tumor cell implantation (prior to any treatment). All mice in
the PBS-treated control group were CTC positive at one or more
time points starting at 5 weeks after tumor cell implantation. In
contrast, only one animal in the GLV-1h68 early treatment group
had any detectable CTC’s after virus treatment (3, 1, and 2 CTCs
at 2, 3, and 4 weeks after treatment, respectively, Figure 4A).
Thus, early treatment significantly reduced CTC formation in
mice bearing human prostate cancer tumors.
Mice in the late treatment group had a significant number of
CTCs before virus treatment, ranging from 12 to 103 CTCs per
80 mL of blood. A dramatic decrease in CTC numbers was
observed one week after virus treatment (Figure 4B). Interestingly,
at 1 week after treatment, 52.9% of CTCs were GFP positive, thus
were infected by GLV-1h68. At 2 weeks after treatment, the
number of CTCs remained at reduced levels, and almost all CTCs
(99.6%) were GFP positive (Figure 4C).
Figure 2. Characterization of CTCs in blood samples detected with GLV-1h254. (A) The CTCs in mice bearing human PC-3 prostate cancer
xenografts showed high-level expression of CD44, ALDH1, vimentin and N-cadherin. (B) The CTCs from the human metastatic breast cancer patient
BC1 showed the strong expression of CD44. (C) The live CTCs in the human metastatic breast cancer patient BC5 showed the strong expression of
ALDH1.
doi:10.1371/journal.pone.0071105.g002
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Figure 3. Detection and identification of live tumor cells in a CSF sample. (A) The live tumor cells in the CSF sample of a patient with
metastatic breast cancer were identified as TurboFP635+/CK+/DAPI+ cells. (B) A live cancer cell cluster with heterogeneous expression of CK in the CSF
sample was identified by VACV.
doi:10.1371/journal.pone.0071105.g003
Figure 4. Prevention and therapy of CTCs in mice bearing human prostate cancer. (A) GLV-1h68 early treatment prevented CTC formation
in the majority of mice (7/8) while mice in the PBS group showed an increase in CTC numbers. (B) GLV-1h68 late treatment resulted in a dramatic
decrease in CTC numbers while CTC numbers in the PBS group increased greatly, and then fluctuated over time. (C) Almost all CTCs detected in the
GLV-1h68 late treatment group were GFP-positive (infected) at two weeks after treatment. (D) Primary tumors regressed after GLV-1h68 early or late
treatment. (E) Both GLV-1h68 early and late treatments significantly prolonged mouse survival (p = 0.002, GLV-1h68 early vs. PBS; p = 0.006 GLV-1h68
late vs. PBS).
doi:10.1371/journal.pone.0071105.g004
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While primary tumors kept growing in the PBS group, both
early and late treatments with GLV-1h68 resulted in tumor
regression (Figure 4D) and significantly prolonged survival in
comparison with PBS treatment (Figure 4E). The average survival
days were 126.3 and 97.3 days for the early and late treatment
groups, respectively, versus 52.7 days for the PBS treatment group.
At death or at the end of the experiment, all mice were dissected
and metastases were examined under a fluorescent stereo
microscope. All mice in the PBS group had detectable lumbar
and renal lymph node metastases (Figure S3). In contrast, only one
out of 8 mice in the early treatment group had a slightly enlarged
lumbar lymph node, the other mice in this group had no
detectable lumbar or renal lymph node metastases. Although all
mice in the late treatment group had detectable lumbar and renal
lymph node metastases, these metastases were smaller in size
compared to the PBS group.
Therapy of Metastatic Cancer Cells in the Ascites of a
Patient with PC from Gastric Cancer
Tumor cell-containing ascites from a patient with PC from
gastric cancer were isolated three and seven days after the first
intraperitoneal treatment with 107 pfu of GL-ONC1 (clinical
version of GLV-1h68). Ascitic cells were fixed in buffered
formalin, and a cell block was made and paraffin embedded.
Paraffin sections were stained with haematoxylin and eosin for
morphologic evaluation. Using either anti-EpCAM or anti-
vaccinia specific antibodies, around 5% of all cells were found to
be EpCAM-positive three days after treatment, and only around
5–10% of these cancer cells were VACV positive at the same time
point (Figure 5). The background population showed an evidence
of significant acute inflammation with an increase in neutrophils.
In contrast, four days later (i.e. 7 days after treatment), less than
2% of all ascitic cells were still EpCAM-positive, and more than
90% of these cancer cells were VACV positive. The VACV-
positive cancer cells morphologically showed significant degener-
ative changes (in the process of cell death). These promising results
suggest that GL-ONC1 can effectively remove live tumor cells in
the ascites of patients with PC.
Discussion
Metastatic tumor cells in body fluids such as blood, lymphatic
fluids, CSF, and ascites represent a great challenge for cancer
diagnosis and treatment. Cancer metastasis mediated by meta-
static tumor cells is responsible for more than 90% of cancer
patient deaths [17]. The ability to detect and treat metastatic
tumor cells will have a great impact on reducing cancer-related
morbidity and mortality. In the present study, we demonstrated
the feasibility of using VACV to detect live metastatic tumor cells
in blood from both mouse models and patients with cancer, as well
as in the CSF sample from a patient with breast cancer.
Importantly, VACV was shown to be effective in preventing and
treating CTCs in the mouse model, and in reducing tumor cells in
the ascites of a patient with PC from gastric cancer.
VACV preferentially infects and replicates in cancer cells [8,18].
Cancer cells are fast growing cells that can provide ample
nutrients, such as nucleotide pools, for VACV replication. In
addition, cancer cells lack intact interferon signaling pathways
and/or apoptotic pathways that limit virus replication in healthy
cells. The tumor selectivity of VACV can be further increased
mainly through inactivation of viral genes that are critical for
efficient viral replication in healthy cells, but are dispensable upon
infection of cancer cells [8]. VACV is known to infect various types
of cancer cells. VACV enters cells through either plasma
membrane fusion or macropinocytosis after attaching to cell
surface glycosaminoglycans or extracellular matrix protein laminin
[19]. The entry pathways are virus strain and cell type-dependent.
Although several cellular proteins have been indicated to
participate in VACV entry, their significance is not fully revealed.
These proteins might be required for the specific VACV strains
and cell types used. The cellular receptors shared by all poxviruses
have yet to be identified. The use of redundant attachment modes
and alternative entry pathways may contribute to the ability of
VACV to infect a broad range of cancer cells. The recombinant
vaccinia virus employed for the detection of metastatic tumor cells
in this study was GLV-1h254 that expresses TurboFP635
(Katushka) under the control of the VACV strong synthetic late
promoter for easy and sensitive detection of infected cells.
TurboFP635 is a bright far-red fluorescent protein (seven to ten
fold brighter than HcRed and mPlum), characterized by fast
maturation and a high photo stability [20]. These features make it
an ideal protein for visualization and detection of infected tumor
cells. The vaccinia strong synthetic late promoter was intentionally
selected to control the expression of TurboFP635, not only to
achieve high-level expression of the protein, but also to avoid
visualizing infected healthy blood cells. VACV is known to infect
monocytes, B lymphocytes and natural killer cells in which
infection is abortive, resulting in the expression of only early viral
proteins, but not late proteins [21]. To evaluate the tumor cell
specificity of GLV-1h254, whole blood samples from six healthy
human and mouse donors were infected with GLV-1h254 after
red blood cell lysis. No TurboFP635-expressing cells were found.
Furthermore, when pre-labeled tumor cells were spiked into whole
blood samples from healthy human and mouse donors, only spiked
tumor cells showed strong TurboFP635 fluorescent signals.
Importantly, GLV-1h254-infected cells found in whole blood
samples from human cancer patients with metastatic breast
cancer, colorectal cancer, lung cancer and melanoma and from
mice bearing human lung and prostate tumors were confirmed to
be CTCs by immunostaining for epithelial cell biomarkers, such as
CK and EpCAM, or tumor-specific antigens. Thus, GLV-1h254 is
highly tumor cell-specific for the detection of human CTCs in both
patients with cancer and in mice bearing human cancer
xenografts.
Most of the widely used CTC assays are based on the detection
of epithelial cell markers such as CK and/or EpCAM [2].
Theoretically, these assays can detect both cancerous and healthy
epithelial cells circulating in the peripheral blood and, therefore,
are not strictly cancer-specific. Additionally, down-regulation of
EpCAM and CK was seen for CTCs in the peripheral blood [22–
25]. Thus, CTC detection assays using EpCAM and/or CK as
biomarkers, such as the FDA-approved CellSearchH system, may
only detect CTCs with high-level expression of EpCAM and/or
CK while CTCs with low-level expression of these biomarkers or
CTCs that do not express these biomarkers will be left undetected.
Furthermore, the performance of antibody-based assays relies on
the quality of antibodies and pre-validation of each antibody is
required. On the contrary, infection of CTCs with VACV is
independent of the expression of biomarkers, such as EpCAM and
CK, thus, detection of CTCs with VACV eliminates bias related
to the use of antibodies, and VACV can be potentially used to
detect CTCs of any tumor type, not limited to CTCs of epithelial
origin.
The VACV-cytospin assay only detects live CTCs, whereas
CellSearchH system identifies CTCs irrespective of their viability.
The performance of the CellSearch system has been previously
evaluated [13]. In a side-by-side comparison of the VACV-
cytospin assay and the CellSearchH system, blood samples from 10
Detection and Therapy of Metastatic Tumor Cells
PLOS ONE | www.plosone.org 8 2013 | Volume 8 | Issue 9 | e71105September
patients with breast or colon cancer were tested. CTCs were
enumerated independently by the two methods. Both methods
detected CTCs in patients 1 to 4, but not in patients 5, 6, 8, 9 and
10. In addition, the VACV-cytospin assay detected 2 CTCs in
patient 7, but no CTCs were detected in this patient by the
CellSearchH system. In patients 1 and 2, the VACV-cytospin assay
detected a slightly higher number of CTCs than did the
CellSearchH system, suggesting that detection efficiency of the
VACV-cytospin assay was comparable to or slightly higher than
that of the CellSearchH system. In patient 3, a slightly lower
number of CTCs were detected by the VACV-cytospin assay as
compared to the CellSearchH system. Intriguingly, in patient 4,
103 CTCs were enumerated by the CellSearchH system while only
5 CTCs were found by the VACV-cytospin assay in a 7.5 mL
blood sample from the same blood draw, indicating that most of
CTCs in the patient 4 might have been dead. The timing of cell
death in this case is not apparent from this analysis. It is possible,
however unlikely, that the CTCs in this patient were killed after
obtaining the blood sample, although appreciable numbers of non-
live cells were not found in any other patient samples and all
samples were handled and processed in the same manner.
Alternatively, non-live CTCs may be prevalent in the circulation
of some cancer patients. Use of the VACV-cytospin assay in
combination with the CellSearchH assay could offer a tool to
investigate the frequency and possible significance of this
occurrence. Live CTCs detected by the VACV-cytospin assay
might be more clinically relevant than total CTCs identified by the
CellSearchH system since only live CTCs can potentially initiate
new metastases.
Cancer metastasis is a comprehensive process that involves
CSCs, EMT, and CTCs [26]. It seems that CTCs and CSCs are
not necessarily separate populations of cancer cells, as CTCs
generated in the process of EMT can bear features characteristic
of CSCs [27]. We characterized VACV-identified live CTCs by
immunostaining for CSC markers CD44 and ALDH1 as well as
EMT markers vimentin and N-cadherin. It was found that
VACV-identified CTCs co-expressing these markers, suggesting a
critical role of these CTCs in the formation of cancer metastases.
In addition to the detection of CTCs in blood samples, we were
also able to identify a significant number of metastatic tumor cells
Figure 5. Therapy of cancer cells in the ascites of a cancer patient with peritoneal carcinomatosis. Cell block sections of malignant ascitic
cells were stained with haematoxylin and eosin (A-I, B-I) at three (A) and seven (B) days after virus treatment. EpCAM positive cells in the malignant
ascites sections were detected using an anti-EpCAM antibody (A-II, B-II). GL-ONC1 infection of single cells was detected using an anti-VACV-A27L
antibody (A-III, B-III). Scale bars represent 50 mm.
doi:10.1371/journal.pone.0071105.g005
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in the CSF sample from a patient with late-stage metastatic breast
cancer. Our method can be an important addition to the CSF
analysis currently used in the clinic for the diagnosis of LM [4]. It
is conceivable that the VACV-cytospin assay can be also widely
applied to the detection of metastatic tumor cells in other liquid
biopsies, such as lymphatic, plural, and peritoneal fluids, and even
in bone marrow samples.
Oncolytic adenovirus and herpes simplex virus-1 expressing GFP
have also been developed for the identification of cancer cells in
liquid biopsies [28–31]. Fong et al. reported a proof-of-principle
study demonstrating that a GFP-expressing oncolytic herpes
simplex virus (HSV), NV1066 was able to identify human cancer
cells spiked into samples of whole blood through detection of virus-
mediated GFP expression in infected cancer cells by fluorescence
microscopy and flow cytometry [31]. Infected cancer cells were then
isolated by fluorescence-assisted cell sorting for subsequent molec-
ular characterization. This method allowed detection of as little as
10 cancer cells in 10 mL whole blood. This was the first study
showing the utility of oncolytic viruses for detection of rare cancer
cells in blood samples. A follow-up study from the same lab showed
that cancer cells in pleural fluid samples from two cancer patients
could be detected by the same virus, demonstrating the potential
clinical use of this technique [29]. Its applicability, however, has not
been validated with blood samples from cancer patients. Further-
more, this assay provides only qualitative information about the
presence or absence of cancer cells in liquid biopsy samples. The use
of this assay for quantitative determination of cancer cells needs to
be further investigated. In contrast, we showed that our method was
able to quantitatively enumerate cancer cells in both blood and CSF
samples from patients with various cancers as well as in blood
samples from mice bearing human tumor xenografts. In addition to
HSV, Kojima et al. reported that a telomerase-specific replication-
selective adenovirus expressing GFP, OBP-401, successfully enu-
merated CTCs in blood samples from patients with various types of
cancer [30]. When the OBP-401 assay was compared with the
CellSearch system in detecting CTCs in both early breast cancer
patients and metastatic breast cancer patients, a great discrepancy
in patients with CTCs between both assays were noticed although
the CTC detection rates for the two assays were comparable [28].
Both assays detected CTCs in 15% of the patients with early breast
cancer. None of the patients, however, were positive for both
methods. Among the patients with metastatic breast cancer, only
18% of the patients were identified as positive by both approaches
while 24% and 36% of the patients were identified solely as positive
by the OBP-401 assay or the CellSearch assay, respectively. In
contrast, the VACV-cytospin assay showed a great consistency with
the CellSearch system in patients with CTCs. Four and 5 out of 10
patients were determined to be positive and negative for CTCs,
respectively, by both assays. Only 1 out 10 patients was positive for
the VACV-cytospin assay alone, and negative for the CellSearch
system. The OBP-401 and CellSearch assays might detect different
populations of CTCs in the blood. The CellSearch detects CK+ and
EpCAM+ cells whereas the OBP-401 assay identifies cells that
express the coxsackie adenovirus receptor and telomerase. Due to
the heterogeneous expression of the coxsackie adenovirus receptor
on tumor cells [32], the wide applicability of this virus needs to be
further investigated. Further, hematopoietic stem cells in the
peripheral blood express high-level telomerase, which may cause
false-positive results.
GLV-1h68, possibly one of the best-studied oncolytic vaccinia
viruses, is highly tumor-specific and effective in treating many types
of human and canine tumors in preclinical models [8,33]. GLV-
1h68 has been tested in a phase I clinical trial and is being tested in
more phase I and II trials, demonstrating a safe profile and initial
evidence of anti-tumor activity in cancer patients [34]. Previously,
we have shown that treatment with GLV-1h68 resulted in tumor
regression and reduced lymphatic metastases in mice bearing
human prostate cancer PC3 xenografts [35]. We have further
shown that GLV-1h68 preferentially colonizes metastases com-
pared to primary tumors [9]. In this study, we sought to investigate
how GLV-1h68 treatment can affect CTC formation and its kinetic
change in the same tumor model. To mimic the clinical situation in
patients with early or late stage prostate cancer, mice bearing
human prostate cancer PC3 xenografts were treated with a single
intravenous dose of GLV-1h68 either before or after CTCs were
detected. Surprisingly, GLV-1h68 early treatment completely
prevented CTC formation in 7 out of 8 treated mice. Probably,
early treatment inhibited migration of tumor cells from primary
tumors since no lymph node metastases were detected in these mice.
GLV-1h68 late treatment reduced the number of CTCs, and more
than 50% and nearly 100% of CTCs captured were infected by
GLV-1h68 (GFP positive) at 1 week and at 2 weeks after treatment,
respectively. Smaller and fewer lymph node metastasis were seen in
the late treatment group compared to the PBS control group. Both
early and late treatments with GLV-1h68 resulted in the regression
of primary tumors and significantly prolonged survival in compar-
ison with PBS treatment. In our study, the absence and decreased
number of CTCs were consistent with absent or reduced metastases,
supporting the current hypothesis that in metastatic prostate cancer,
the level of CTCs is strongly related with lymphatic metastases and
overall survival [2].
PC is generally regarded as a fatal disease. In a proof-of-
principle study, a patient with PC from gastric cancer was treated
with a single low dose of GL-ONC1 delivered intraperitoneally.
Interestingly, we found that more than 90% of cancer cells in the
ascites of this patient were infected just 7 days after treatment,
indicating that GL-ONC1 replicates efficiently in situ in the
peritoneal cavity, a very promising result for the possible clearance
of such malignant cells from the peritoneal cavity in patients with
PC.
To our knowledge, this is the first report demonstrating the
feasibility of using VACV to detect live metastatic tumor cells in
liquid biopsies, and to treat these malignant cells in body fluids in
both mouse models and patients with cancer. The VACV-cytospin
assay can potentially be a widely applicable method to detect live
metastatic tumor cells of any tumor type, not limited to those of
epithelial origin. Identification of live metastatic tumor cells in
liquid biopsies may provide valuable diagnostic and prognostic
information specific for each individual patient. Prevention and
elimination of metastatic tumor cells with VACV would result in
great reductions in morbidity and mortality.
Supporting Information
Figure S1 Schematic representation of the genomic
structures of the recombinant VACVs GLV-1h68 and
GLV-1h254. PE/L, PL, P11, and P7.5 are VACV synthetic
early/late, synthetic late, 11K, and 7.5K promoters, respectively.
TfR is a human transferin receptor cDNA inserted in the reverse
orientation with respect to the promoter PE/L.
(TIF)
Figure S2 Characterization of VACV-cytospin assay. (A)
Infection efficiency of PC-3 cells spiked in the mouse and human
blood at escalated doses of virus. (B) GLV-1h254 infected only PC-
3 cells spiked in the whole human blood, but not immune cells
(red: TurboFP635; green: CD45; blue: nuclei).
(TIF)
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Figure S3 The effect of GLV-1h68 on lymphatic metas-
tases in mice bearing human PC3 prostate cancer
xenografts. All mice in the PBS group had detectable lumbar
and renal lymph node metastases. In contrast, early treatment with
GLV-1h68 resulted in the absence of detectable lumbar or renal
lymph node metastases in 7 out of 8 treated mice. Only one out of
8 mice in this group had a slightly enlarged lumbar lymph node.
Although all mice in the late treatment group had detectable
lumbar and renal lymph node metastases, these metastases were
smaller in size compared to the PBS group. LN, lumbar lymph
node metastases; RN, renal lymph node metastases.
(TIF)
Table S1 Capture efficiency, detection efficiency, infec-
tion efficiency and infection specificity of the VACV-
Cytospin assay with both human and mouse blood
samples.
(DOCX)
Table S2 Clinical information of 7 patients with
metastatic breast cancer.
(DOCX)
Table S3 Clinical information of patients with meta-
static rectal cancer, lung cancer and melanoma.
(DOCX)
Table S4 Clinical information of the patients enrolled
in the comparison study.
(DOCX)
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